Invaplex functions as an intranasal adjuvant for subunit and DNA vaccines co-delivered in the nasal cavity of nonhuman primates

[1]  F. Höök,et al.  A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection , 2020, Mucosal Immunology.

[2]  D. Bernstein,et al.  Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults , 2020, Human vaccines & immunotherapeutics.

[3]  Bertrand Z. Yeung,et al.  T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers , 2020, Nature Medicine.

[4]  S. Perlman,et al.  Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection , 2020, mBio.

[5]  C. Locht,et al.  Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans. , 2020, The Journal of clinical investigation.

[6]  Y. Lo,et al.  Depot medroxyprogesterone acetate (Depo-Provera) administration increases cervical CCR5+CD4+ T cells and induces immunosuppressive milieu at the cervicovaginal mucosa: a 3-month longitudinal study. , 2020, AIDS.

[7]  R. Karron,et al.  Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children. , 2019, The Journal of infectious diseases.

[8]  L. Boon,et al.  Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization , 2019, Front. Immunol..

[9]  Jun Chang,et al.  Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus , 2019, Antiviral research.

[10]  A. Nicosia,et al.  Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults , 2019, Journal of Infection.

[11]  G. Doncel,et al.  Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity , 2018, The Journal of clinical investigation.

[12]  E. Oaks,et al.  Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex , 2018, mSphere.

[13]  W. Cao,et al.  Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice , 2017, Vaccine.

[14]  J. Mcnicholl,et al.  A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk , 2016, Journal of acquired immune deficiency syndromes.

[15]  R. Pabst.  Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences. , 2015, Vaccine.

[16]  A. Folgori,et al.  Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates , 2015, Molecular therapy. Methods & clinical development.

[17]  A. Lind,et al.  Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial , 2014, PloS one.

[18]  Z. Hel,et al.  Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. , 2014, Contraception.

[19]  R. Heyderman,et al.  Polysaccharide-Specific Memory B Cells Generated by Conjugate Vaccines in Humans Conform to the CD27+IgG+ Isotype–Switched Memory B Cell Phenotype and Require Contact-Dependent Signals from Bystander T Cells Activated by Bacterial Proteins To Differentiate into Plasma Cells , 2013, The Journal of Immunology.

[20]  Nicole M. Bouvier,et al.  Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs , 2013, Journal of Virology.

[21]  D. Montefiori,et al.  Immunogenicity of a Vaccine Regimen Composed of Simian Immunodeficiency Virus DNA, rMVA, and Viral Particles Administered to Female Rhesus Macaques via Four Different Mucosal Routes , 2013, Journal of Virology.

[22]  B. Walker,et al.  Gag-Specific Cellular Immunity Determines In Vitro Viral Inhibition and In Vivo Virologic Control following Simian Immunodeficiency Virus Challenges of Vaccinated Rhesus Monkeys , 2012, Journal of Virology.

[23]  D. Tribble,et al.  Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. , 2011, Vaccine.

[24]  P. Earl,et al.  Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. , 2011, Vaccine.

[25]  D. Montefiori,et al.  Long-Term Control of Simian Immunodeficiency Virusmac251 Viremia to Undetectable Levels in Half of Infected Female Rhesus Macaques Nasally Vaccinated with Simian Immunodeficiency Virus DNA/Recombinant Modified Vaccinia Virus Ankara , 2011, The Journal of Immunology.

[26]  L. Lopalco,et al.  Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. , 2011, Immunity.

[27]  C. Andrews,et al.  Genetic immunization in the lung induces potent local and systemic immune responses , 2010, Proceedings of the National Academy of Sciences.

[28]  D. Venzon,et al.  Multiple Vaccine-Elicited Nonneutralizing Antienvelope Antibody Activities Contribute to Protective Efficacy by Reducing both Acute and Chronic Viremia following Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques , 2010, Journal of Virology.

[29]  M. McChesney,et al.  Depo-Provera® Treatment Does Not Abrogate Protection from Intravenous SIV Challenge in Female Macaques Immunized with an Attenuated AIDS Virus , 2010, PloS one.

[30]  R. Rappuoli,et al.  Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.

[31]  D. Montefiori,et al.  Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination , 2009, Mucosal Immunology.

[32]  J. Dietrich,et al.  Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose , 2009, PloS one.

[33]  C. Chao,et al.  Mucosal Adjuvanticity of a Shigella Invasin Complex with DNA-Based Vaccines , 2009, Clinical and Vaccine Immunology.

[34]  R. Goldblum,et al.  Human IgA-Inducing Protein from Dendritic Cells Induces IgA Production by Naive IgD+ B Cells1 , 2009, The Journal of Immunology.

[35]  S. Lira,et al.  Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. , 2008, Gastroenterology.

[36]  M. Betts,et al.  Phenotype and function of protective T cell immune responses in HIV , 2008, Current opinion in HIV and AIDS.

[37]  E. Oaks,et al.  Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. , 2008, Vaccine.

[38]  B. Moss,et al.  GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. , 2007, Virology.

[39]  P. Brandtzaeg.  Induction of secretory immunity and memory at mucosal surfaces. , 2007, Vaccine.

[40]  A. Plebani,et al.  Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. , 2007, Immunity.

[41]  C. Cheng‐Mayer,et al.  Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. , 2006, Virology.

[42]  E. Oaks,et al.  Mucosal Adjuvant Properties of the Shigella Invasin Complex , 2006, Infection and Immunity.

[43]  E. Oaks,et al.  Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. , 2006, Vaccine.

[44]  Z. Xing,et al.  Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis1 , 2004, The Journal of Immunology.

[45]  Christopher J. Miller,et al.  Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. , 2004, The Journal of infectious diseases.

[46]  P. Wright,et al.  Role of IgA versus IgG in the Control of Influenza Viral Infection in the Murine Respiratory Tract1 , 2004, The Journal of Immunology.

[47]  D. Montefiori,et al.  Control of Simian/Human Immunodeficiency Virus Viremia and Disease Progression after IL-2-Augmented DNA-Modified Vaccinia Virus Ankara Nasal Vaccination in Nonhuman Primates1 , 2004, The Journal of Immunology.

[48]  A. Ashkar,et al.  Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection , 2003, Journal of Virology.

[49]  R. Rappuoli,et al.  Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A , 2003, Infection and Immunity.

[50]  R. Lynch,et al.  Differential Induction of Mucosal and Systemic Antibody Responses in Women After Nasal, Rectal, or Vaginal Immunization: Influence of the Menstrual Cycle1 , 2002, The Journal of Immunology.

[51]  R. Jonsson,et al.  Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. , 2002, The Journal of infectious diseases.

[52]  Y. Iwakura,et al.  Protection Against Influenza Virus Infection in Polymeric Ig Receptor Knockout Mice Immunized Intranasally with Adjuvant-Combined Vaccines , 2002, The Journal of Immunology.

[53]  David N. Taylor,et al.  Safety and Immunogenicity of a Proteosome-Shigella flexneri 2a Lipopolysaccharide Vaccine Administered Intranasally to Healthy Adults , 2001, Infection and Immunity.

[54]  E. Oaks,et al.  Isolation and Characterization of a Shigella flexneri Invasin Complex Subunit Vaccine , 2000, Infection and Immunity.

[55]  D. Montefiori,et al.  Effective Induction of Simian Immunodeficiency Virus-Specific Systemic and Mucosal Immune Responses in Primates by Vaccination with Proviral DNA Producing Intact but Noninfectious Virions , 2000, Journal of Virology.

[56]  R. Lynch,et al.  Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. , 2000, Journal of acquired immune deficiency syndromes.

[57]  T. Rourke,et al.  Immunoglobulin Concentrations and Antigen-Specific Antibody Levels in Cervicovaginal Lavages of Rhesus Macaques Are Influenced by the Stage of the Menstrual Cycle , 1999, Infection and Immunity.

[58]  J. Holmgren,et al.  Antibody Responses in the Lower Respiratory Tract and Male Urogenital Tract in Humans after Nasal and Oral Vaccination with Cholera Toxin B Subunit , 1999, Infection and Immunity.

[59]  R. Alvarez,et al.  Differences in Immune Responses Induced by Oral and Rectal Immunizations with Salmonella typhi Ty21a: Evidence for Compartmentalization within the Common Mucosal Immune System in Humans , 1998, Infection and Immunity.

[60]  C. Czerkinsky,et al.  Specific-Antibody-Secreting Cells in the Rectums and Genital Tracts of Nonhuman Primates following Vaccination , 1998, Infection and Immunity.

[61]  J. Holmgren,et al.  Differential Kinetics and Distribution of Antibodies in Serum and Nasal and Vaginal Secretions after Nasal and Oral Vaccination of Humans , 1998, Infection and Immunity.

[62]  C. Czerkinsky,et al.  Antibodies and Antibody-Secreting Cells in the Female Genital Tract after Vaginal or Intranasal Immunization with Cholera Toxin B Subunit or Conjugates , 1998, Infection and Immunity.

[63]  E. Partridge,et al.  Rectal Immunization for Induction of Specific Antibody in the Genital Tract of Women , 1997, Journal of Clinical Immunology.

[64]  T. Flanigan,et al.  Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women , 1997, Infection and immunity.

[65]  E. Butcher,et al.  Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. , 1997, The Journal of clinical investigation.

[66]  J. Mestecky,et al.  Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation , 1996, Clinical and experimental immunology.

[67]  P. Sansonetti,et al.  Molecular and Cellular Mechanisms of Tissue Invasion by Shigella flexneri a , 1994, Annals of the New York Academy of Sciences.

[68]  P. Small,et al.  Passive transfer of local immunity to influenza virus infection by IgA antibody. , 1991, Journal of immunology.

[69]  D. Sharp,et al.  Use of Medroxyprogesterone Acetate as a Contraceptive in conjunction with Early Postpartum Rubella Vaccination , 1973, British medical journal.

[70]  A. Lackner,et al.  Oral immunization studies with Streptococcus mutans and influenza vaccines in rhesus macaque monkeys. , 1995, Advances in Experimental Medicine and Biology.

[71]  岡田 正次郎,et al.  Shigella flexneri 2の抗原変異 , 1959 .